MX2015014083A - Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). - Google Patents
Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1).Info
- Publication number
- MX2015014083A MX2015014083A MX2015014083A MX2015014083A MX2015014083A MX 2015014083 A MX2015014083 A MX 2015014083A MX 2015014083 A MX2015014083 A MX 2015014083A MX 2015014083 A MX2015014083 A MX 2015014083A MX 2015014083 A MX2015014083 A MX 2015014083A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- bace1 inhibitors
- bace1
- alzheimer
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona un compuesto de fórmula I que tiene actividad inhibidora BACE1, su fabricación, composiciones farmacéuticas que lo contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo la enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13163430 | 2013-04-11 | ||
PCT/EP2014/056985 WO2014166906A1 (en) | 2013-04-11 | 2014-04-08 | Bace1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015014083A true MX2015014083A (es) | 2016-07-26 |
Family
ID=48050604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015014083A MX2015014083A (es) | 2013-04-11 | 2014-04-08 | Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). |
Country Status (20)
Country | Link |
---|---|
US (1) | US11447478B2 (es) |
EP (1) | EP2984086A1 (es) |
JP (2) | JP6574756B2 (es) |
KR (1) | KR102247765B1 (es) |
CN (1) | CN105431430B (es) |
AU (1) | AU2014253275B2 (es) |
BR (1) | BR112015019412A8 (es) |
CA (1) | CA2900433C (es) |
CL (1) | CL2015002897A1 (es) |
EA (1) | EA027860B1 (es) |
HK (1) | HK1216533A1 (es) |
IL (2) | IL240263A0 (es) |
MA (2) | MA44948A1 (es) |
MX (1) | MX2015014083A (es) |
MY (1) | MY174747A (es) |
PE (1) | PE20151748A1 (es) |
PH (1) | PH12015502365A1 (es) |
SG (1) | SG11201508412XA (es) |
UA (1) | UA119141C2 (es) |
WO (1) | WO2014166906A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
AU2014223334C1 (en) * | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
MX2015011618A (es) | 2013-03-08 | 2015-12-17 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
CA2957544C (en) | 2014-08-08 | 2023-01-24 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
JP2017071603A (ja) * | 2015-10-09 | 2017-04-13 | 塩野義製薬株式会社 | ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物 |
WO2017148878A1 (en) | 2016-03-01 | 2017-09-08 | F. Hoffmann-La Roche Ag | Bace 1 inhibitors |
JP7353708B2 (ja) | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
KR102467525B1 (ko) | 2020-11-26 | 2022-11-14 | 이대근 | 작업자 중개 장치 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
EP2155747B1 (en) | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
CN101910143B (zh) | 2008-01-18 | 2013-08-21 | 卫材R&D管理有限公司 | 稠合的氨基二氢噻嗪衍生物 |
JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
US8999980B2 (en) * | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
ME02409B (me) | 2011-01-13 | 2016-09-20 | Novartis Ag | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
RU2599256C2 (ru) | 2011-06-07 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | [1,3]оксазины |
CN103717592A (zh) | 2011-06-07 | 2014-04-09 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的卤代-烷基-1,3噁嗪类 |
UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
MX354173B (es) | 2012-01-26 | 2018-02-16 | Hoffmann La Roche | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas. |
JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
-
2014
- 2014-04-08 CN CN201480019357.2A patent/CN105431430B/zh active Active
- 2014-04-08 MA MA44948A patent/MA44948A1/fr unknown
- 2014-04-08 EA EA201591541A patent/EA027860B1/ru not_active IP Right Cessation
- 2014-04-08 EP EP14715908.1A patent/EP2984086A1/en not_active Withdrawn
- 2014-04-08 PE PE2015002129A patent/PE20151748A1/es unknown
- 2014-04-08 US US14/783,478 patent/US11447478B2/en active Active
- 2014-04-08 JP JP2016506890A patent/JP6574756B2/ja active Active
- 2014-04-08 BR BR112015019412A patent/BR112015019412A8/pt not_active Application Discontinuation
- 2014-04-08 MX MX2015014083A patent/MX2015014083A/es unknown
- 2014-04-08 KR KR1020157031878A patent/KR102247765B1/ko active IP Right Grant
- 2014-04-08 SG SG11201508412XA patent/SG11201508412XA/en unknown
- 2014-04-08 WO PCT/EP2014/056985 patent/WO2014166906A1/en active Application Filing
- 2014-04-08 CA CA2900433A patent/CA2900433C/en active Active
- 2014-04-08 AU AU2014253275A patent/AU2014253275B2/en active Active
- 2014-04-08 MY MYPI2015002528A patent/MY174747A/en unknown
- 2014-04-08 MA MA38556A patent/MA38556A1/fr unknown
- 2014-08-04 UA UAA201510494A patent/UA119141C2/uk unknown
-
2015
- 2015-07-30 IL IL240263A patent/IL240263A0/en active IP Right Grant
- 2015-09-29 CL CL2015002897A patent/CL2015002897A1/es unknown
- 2015-10-12 PH PH12015502365A patent/PH12015502365A1/en unknown
-
2016
- 2016-04-20 HK HK16104540.9A patent/HK1216533A1/zh unknown
-
2018
- 2018-10-16 JP JP2018194983A patent/JP6681451B2/ja active Active
-
2019
- 2019-03-20 IL IL265496A patent/IL265496A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2900433C (en) | 2021-06-22 |
UA119141C2 (uk) | 2019-05-10 |
AU2014253275A1 (en) | 2015-07-16 |
AU2014253275B2 (en) | 2018-10-18 |
JP6681451B2 (ja) | 2020-04-15 |
JP6574756B2 (ja) | 2019-09-11 |
BR112015019412A2 (pt) | 2017-07-18 |
CL2015002897A1 (es) | 2016-06-03 |
EA201591541A1 (ru) | 2016-02-29 |
PH12015502365B1 (en) | 2016-02-22 |
EA027860B1 (ru) | 2017-09-29 |
MA38556A1 (fr) | 2017-09-29 |
WO2014166906A1 (en) | 2014-10-16 |
CN105431430A (zh) | 2016-03-23 |
KR20150142001A (ko) | 2015-12-21 |
KR102247765B1 (ko) | 2021-05-06 |
JP2016515638A (ja) | 2016-05-30 |
US20160052920A1 (en) | 2016-02-25 |
MA44948A1 (fr) | 2020-06-30 |
HK1216533A1 (zh) | 2016-11-18 |
EP2984086A1 (en) | 2016-02-17 |
MY174747A (en) | 2020-05-13 |
BR112015019412A8 (pt) | 2019-11-12 |
IL265496A (en) | 2019-05-30 |
JP2019031532A (ja) | 2019-02-28 |
US11447478B2 (en) | 2022-09-20 |
NZ710050A (en) | 2021-03-26 |
CN105431430B (zh) | 2019-05-28 |
PH12015502365A1 (en) | 2016-02-22 |
CA2900433A1 (en) | 2014-10-16 |
SG11201508412XA (en) | 2015-11-27 |
IL240263A0 (en) | 2015-09-24 |
PE20151748A1 (es) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
PH12015502365B1 (en) | Bace1 inhibitors | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
MX2013013692A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2). | |
PH12014501334A1 (en) | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
MX2013010795A (es) | 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2). | |
MX2013014007A (es) | [1,3] oxazinas. | |
PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
MX2013008478A (es) | 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2). | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
PH12017501668A1 (en) | Bace1 inhibitors | |
MX365292B (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas. | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز |